Immunotherapy Stocks List

Immunotherapy Stocks Recent News

Date Stock Title
May 6 CLDX Celldex GAAP EPS of -$0.56, revenue of $0.16M
May 6 CLDX Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 6 SABS SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 6 IMUX Immunic to Participate in Investor and Scientific Conferences in May
May 5 URGN New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
May 4 URGN UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
May 4 URGN New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
May 3 PDSB PDS Biotechnology Announces Details of Virtual KOL Event
May 3 URGN UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
May 2 PDSB PDS Biotechnology names Stephan Toutain as COO
May 2 PDSB PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
May 1 IMUX Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
May 1 IMUX Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
Apr 30 CERO CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes
Apr 30 IMUX Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
Immunotherapy

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags